The Relationship between the Expression of SATB1 and Clinicopathological Features and Prognosis of Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.05.016
- Author:
Jie SUN
1
;
Guang-Yao YU
2
;
Sha HE
1
;
Xiao-Hong TAN
1
Author Information
1. Department of Hematology/Oncology and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
2. Department of Hematology, Nanning First People's Hospital, Nanning 530000, Guangxi Zhuang Autonomous Region, China.
- Publication Type:Journal Article
- Keywords:
SATB1;
diffuse large B-cell lymphoma;
clinicopathological features;
prognosis
- MeSH:
Humans;
Lymphoma, Large B-Cell, Diffuse/metabolism*;
Matrix Attachment Region Binding Proteins/metabolism*;
Prognosis;
Female;
Male;
Middle Aged;
Immunohistochemistry;
Adult
- From:
Journal of Experimental Hematology
2025;33(5):1344-1349
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the expression of specific AT sequence binding protein 1 (SATB1) in diffuse large B cell lymphoma (DLBCL) and its relationship with clinicopathological features and prognosis.
METHODS:A total of 68 cases of initially diagnosed with DLBCL at Guangxi Medical University Affiliated Tumor Hospital between January 2008 to December 2015 were enrolled. The expression of SATB1 were detected by Immunohistochemistry on paraffin embedded tissue of patients. The relationship between the expression of SATB1 and clinicopathological features and prognosis in patients with DLBCL was analyzed.
RESULTS:SATB1 protein was mainly expressed in cytoplasm of lymphoma cell. The rate of SATB1 expression in DLBCL tissues was 66.2% (46/68). The positive rate of SATB1 in patients with ECOG score of 0-1 was higher than that in patients with ECOG score ≥2 (P <0.05). The 5-year progression-free survival (PFS) and 5-year overall survival (OS) in positive and negative SATB1 groups were 55.5% and 23.5%, respectively (P =0.045), and 65.6% and 34.9%, respectively (P <0.001). Univariate analysis showed that positive expression of SATB1 was associated with good OS of patients. Multivariate analysis showed that chemotherapy cycles less than 4 and elevated LDH were independent adverse prognostic factor for OS in DLBCL patients, with positive SATB1 expression as a protective factor.
CONCLUSION:The positive expression of SATB1 is closely associated with a lower ECOG score and a favorable prognosis in patients with DLBCL.
